Peter L. Salgo, MD: Let’s go back to the clinical experience. We have 2 nephrologists who are clearly using these drugs. Why don’t you, Dr Coyne and Dr Provenzano, give us some anecdotal evidence, if ...
A payer perspective of factors to consider when creating drug policies for HIF stabilizers for patients with anemia in CKD. Transcript Peter L. Salgo, MD: Let me turn this over to Dr Crittenden. What ...
With the U.S. FDA go-ahead Feb. 2 for GSK plc’s oral daprodustat for anemia in patients with chronic kidney disease (CKD), the picture brightened for would-be competitors in the hypoxia-inducible ...
ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO 2 VATE, Akebia’s global ...
Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), ...
Please provide your email address to receive an email when new articles are posted on . During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to ...
Adhering to the recommendation of a mixed advisory committee vote, the U.S. FDA cleared use of GSK plc’s daprodustat as the first oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) inhibitor ...
Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The ...
TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO ...
Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback